Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2026 07:24 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
March 11, 2026 07:00 ET | Source: Vima Therapeutics

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst...
March 10, 2026 09:00 ET | Source: Egg Medical, Inc.

Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection

Egg Medical's Late-Breaker at CRT 2026 proves the EggNest™ reduces scatter radiation, allowing the interventional team to safely work lead-apron free.
March 10, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
March 10, 2026 04:30 ET | Source: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
March 05, 2026 08:00 ET | Source: Tangram Therapeutics PLC

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 ...
March 05, 2026 07:00 ET | Source: Herantis Pharma plc

Herantis Pharma releases 2H and FY 2025 report today

Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies...
March 05, 2026 05:00 ET | Source: Priavoid GmbH

Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PD™ 2026

Dusseldorf, Germany, March 5, 2026 - Priavoid GmbH (“Priavoid”) today announced it will present promising initial safety data from the ongoing Phase 2 trial (PRImus-AD, NCT06182085) evaluating its...
March 05, 2026 03:03 ET | Source: Nxera Pharma

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development...
March 04, 2026 10:57 ET | Source: FemPulse

FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference

SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal...